If you read the morning 5 things to watch each day, you may often see a reference to ASX 200 futures.

They are usually mentioned in articles about what to watch before the Australian share market opens.

But what are they actually telling investors?

ASX 200 futures explained

ASX 200 futures are contracts linked to the S&P/ASX 200 Index (ASX: XJO).

The ASX 200 tracks 200 of the largest companies listed on the Australian share market, including banks, like Commonwealth Bank of Australia (ASX: CBA), miners like BHP Group Ltd (ASX: BHP), healthcare shares like CSL Ltd (ASX: CSL), retailers, property groups, infrastructure businesses, and industrial companies.

A futures contract allows traders to take a view on where that index may be heading.

If ASX 200 futures are pointing higher before the market opens, it suggests traders expect the Australian share market to start the day stronger. If they are pointing lower, it suggests the market may open weaker.

This is why they are often used as a quick guide to early market sentiment.

Why are they watched each morning?

The Australian share market does not trade overnight, but global markets keep moving.

Wall Street may rise or fall while Australian investors are sleeping. Commodity prices can shift. Bond yields, currencies, company earnings, and geopolitical news can all change before the local market opens.

ASX 200 futures respond to some of that information.

They give investors an early clue about how the market may react when trading begins.

This essentially helps set the scene before the opening bell.

Do futures always predict the market correctly?

ASX 200 futures can be useful, but they are only a guide.

The market can open differently from what futures suggest. It can also change direction quickly once trading begins.

That can happen because company-specific news, economic data, broker notes, dividend updates, and investor flows can all affect the market after the open.

For example, futures might suggest a weak start because Wall Street fell overnight. But if major mining shares rise on stronger commodity prices, or a large bank rallies on a positive update, the ASX 200 could perform better than expected.

The reverse can also happen.

Futures help investors understand the mood before the market opens, but they do not guarantee the outcome.

Who uses ASX 200 futures?

Futures are mainly used by professional traders, fund managers, and institutions.

They can be used to hedge portfolios, manage risk, or take short-term views on the direction of the market.

For everyday investors, the main value is informational.

What should investors take from them?

ASX 200 futures are best viewed as a morning temperature check.

They show where traders think the market may be heading before the ASX opens, based on overnight developments and early positioning.

A positive futures move can point to a stronger start. A negative move can signal a softer opening. But the actual trading day will still be shaped by company news, sector moves, economic data, and investor behaviour.

The post What are ASX 200 futures? appeared first on The Motley Fool Australia.

More reading

• Another CSL blow: Why this beaten-up ASX giant is sliding again
• Atlas Arteria reacts to Dulles Greenway litigation outcome
• Here’s the earnings forecast out to 2027 for CBA shares
• Why Rio Tinto shares could be a smart long-term buy
• BHP shares have lost momentum. Should investors be worried?

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended BHP Group and CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

ASX biotech stock Neuren Pharmaceuticals Ltd (ASX: NEU) is flying on Monday.

The ASX biotech stock jumped around 30% to $15.92 in morning trade after announcing a major regulatory breakthrough in Europe for its lead drug, DAYBUE.

Despite today’s rally, Neuren shares remain down approximately 15% in 2026. Over the past 12 months, however, the ASX biotech stock has gained around 17%, comfortably outperforming the S&P/ASX 200 Index (ASX: XJO), which has risen about 3% over the same period.

So, what has investors so excited?

A major step towards European approval

Neuren revealed that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorisation for DAYBUE following a re-examination process.

The recommendation now moves to the European Commission, which is expected to make a final decision over the coming months.

If approved, DAYBUE would become the first authorised treatment for the neurobehavioral symptoms of Rett syndrome across all 27 European Union member states, as well as Iceland, Liechtenstein, and Norway.

For the ASX biotech stock, the financial implications could be significant.

Why the decision matters

Neuren is a biotechnology company developing treatments for rare neurological disorders.

Its most advanced medicine is DAYBUE (trofinetide), which has been licensed to Acadia Pharmaceuticals Inc (NASDAQ: ACAD) for commercialisation.

If the European Commission grants marketing approval and DAYBUE launches in Europe, Neuren will receive a US$35 million milestone payment following the first commercial sale.

The company would also become eligible for ongoing royalties on net sales and additional milestone payments if future sales targets are achieved.

That prospect helps explain today’s enthusiastic share price reaction.

European approval would open another major market for DAYBUE. Earlier, it launched in the US, creating a fresh revenue stream without Neuren needing to fund sales and marketing itself.

At its FY25 results, the ASX biotech stock reported $65 million in royalty income. It expects further growth in 2026 as DAYBUE sales expand. Acadia has guided for DAYBUE net sales of US$460 to US$490 million this year, implying another strong year of royalty growth for Neuren.

What management said

Neuren CEO Jon Pilcher welcomed the recommendation, saying:

I am so delighted for all stakeholders to see this positive outcome from the CHMP re-examination process recommending marketing authorisation for DAYBU® in the EU. With no approved treatment currently available in the EU, approval of DAYBU® would represent an important step forward for patients, caregivers and the wider Rett syndrome community profoundly impacted by this devastating condition.

What’s next for the ASX biotech stock?

While the CHMP recommendation is an important milestone, it is not the final step.

The European Commission must still formally approve the application, with a decision expected in the coming months.

If that happens, the ASX healthcare share would gain access to one of the world’s largest pharmaceutical markets. It would also unlock valuable milestone payments and recurring royalty income.

For investors, today’s rally reflects growing confidence that DAYBUE is edging closer to another major commercial opportunity.

The post Why this ASX biotech stock is soaring 30% today appeared first on The Motley Fool Australia.

More reading

• Leading brokers name 3 ASX shares to buy today
• Bell Potter says this ASX healthcare share could rise 93% (It’s not CSL)
• 5 things to watch on the ASX 200 on Monday
• Here are the top 10 ASX 200 shares today
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

There was a time when CSL Ltd (ASX: CSL) could almost do no wrong in the eyes of investors.

But that now feels like a very long time ago.

At the time of writing, the CSL share price is down 1.77% to $112.85.

This comes after the biotech giant released another disappointing update tied to its Vifor business.

It is the latest blow in what has become an absolute brutal period for one of the ASX’s former market darlings.

CSL shares are now down around 34% since the start of 2026 and have fallen more than 50% over the past year.

So, what’s the latest to go wrong?

CSL’s Vifor troubles deepen in Europe

According to the release, CSL said a European Medicines Agency committee has recommended that marketing authorisation for TAVNEOS be revoked in the European Union (EU).

TAVNEOS, also known as avacopan, is sold by CSL Vifor affiliates in the EU and European Economic Area (EEA) under a licence agreement.

The treatment is used for adults with severe, active ANCA-associated vasculitis, a rare disease that causes inflammation in small and medium blood vessels.

The recommendation follows a review into the handling of data in the pivotal Phase 3 ADVOCATE clinical trial, which supported the product’s approval.

CSL said the European Commission will now review the committee’s opinion and make a final decision in due course.

In the meantime, the company expects to stop new patient starts in EU and EEA markets, in line with regulatory guidance.

Management commentary

CSL said it was disappointed with the outcome, but will respect the regulatory process.

Bill Mezzanotte, CSL’s head of research and development, noted that the company recognises this is a difficult moment for the community.

He said:

Patient care remains our highest priority, and we are working closely with regulatory authorities, healthcare professionals and patient organisations.

CSL advised that sales revenue from TAVNEOS is expected to be approximately US$45 million in FY26.

The company will provide more detail on the intellectual property impairment linked to TAVNEOS when it reports its FY26 full-year results on 18 August.

CSL also pointed out that today’s announcement doesn’t change the estimated impairment it provided to investors in May.

Why this still hurts

Despite the setback , keep in mind that TAVNEOS is tiny next to CSL’s broader global operations.

However, Vifor has already been a major frustration for investors after CSL flagged large write-downs earlier this year.

So, another issue from the same part of the business was never going to land well.

CSL is still a global biotech heavyweight, with major plasma, vaccine, and iron deficiency businesses. Its market capitalisation also remains above $54.5 billion, so this isn’t a business suddenly running out of options.

Nonetheless, investor trust has already been severely damaged.

The post Another CSL blow: Why this beaten-up ASX giant is sliding again appeared first on The Motley Fool Australia.

More reading

• End of financial year is upon us. Here’s what you should do before the deadline
• Why US stocks have hit record highs while ASX shares have barely risen in 2026
• Why this fundie is overweight CSL and underweight CBA shares
• 3 ASX blue chip shares to buy and hold for the next 20 years
• Once untouchable, now unloved: What’s up with CSL shares?